patent.fyi
Applications  /  US 2026/0355307
United States Patent Application Publication

US 2026/0355307 A1

Published
Nov 12, 2026
Filed
Oct 18, 2023
Earliest date on the face
Oct 25, 2022
Classification
A61K 39/39
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Purified protein subunit

What ifWhat if a purified protein subunit supplies the antigen?
Claim language“a pathogen or a live vaccine thereof”

A purified soluble protein supplies the epitopes recognized by antibodies. An enteric coating releases the protein formulation in the intestine.

1.1Cell free antigen assembly

What ifWhat if the antigen comes from cell free assembly and the process omits inactivation?
Claim language“inactivated by permeabilization of the plasma membrane”

Purified protein subunits assemble into particles that display repeated copies of a surface epitope. The particles contain protein and carry no genome.

1.2Polymer antigen carrier

What ifWhat if a biodegradable polymer particle carries the antigen?
Claim language“a permeabilized plasma membrane”

A poly(lactic-co-glycolic acid) particle encapsulates a purified protein antigen in a solid matrix. Water enters the matrix, and polymer hydrolysis contributes to antigen release.

1.2Soluble peptide on beads

What ifWhat if a soluble peptide attached to a solid bead supplies the antigenic surface?
Claim language“its integral membrane protein”

A hydrophilic spacer links a synthetic peptide to a biodegradable polysaccharide bead. Multiple peptide copies on the bead expose the epitope to antibody binding.

1.3Synthetic carbohydrate antigen

What ifWhat if a synthetic carbohydrate linked to a carrier protein supplies the antigen?
Claim language“a pathogen comprising a plasma membrane”

A covalent linker attaches copies of a short synthetic glycan to a soluble carrier protein. The glycan provides the antibody binding surface, and the carrier supplies peptides for helper T cell recognition.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Permeable vesicles for laboratory training

Synthetic lipid vesicles contain an encapsulated fluorescent dye and a reconstituted integral membrane protein with an outward-facing epitope. A lipopeptide surfactant permeabilizes the vesicles in a training cartridge. Learners measure dye release in the liquid and use a labeled antibody to detect the membrane protein on the remaining vesicles.

Component substitution

Saponin replaces the lipopeptide surfactant

Cholesterol-containing synthetic vesicles carry an integral membrane protein and an encapsulated fluorescent tracer. A steroidal saponin replaces the lipopeptide surfactant and increases membrane permeability through interactions with membrane cholesterol. A fluorescence assay measures tracer release, and an antibody-binding assay measures retention of an exposed protein epitope on the vesicles.

Parameter or scale variation

Two vesicle diameters in parallel

Two synthetic vesicle suspensions use the same lipid composition, integral membrane protein and encapsulated dye. Extrusion through membranes with nominal pore diameters of 100 and 400 nanometers produces two size populations, and dynamic light scattering measures their actual diameters. An assay plate holds 100 microliters per well and uses three replicate wells per size and treatment condition to compare fractional dye release after lipopeptide exposure.

Combination with existing systems

Vesicle separation by size exclusion

A size-exclusion chromatography system receives a suspension of synthetic vesicles that carry an integral membrane protein and an encapsulated dye after lipopeptide treatment. The column separates the vesicles into early fractions and the released dye into later fractions. A fraction collector supplies the early fractions for an antibody-binding assay and the later fractions for fluorescence measurement.

Vesicle testing in a simulated gut

A two-stage dissolution apparatus exposes lipopeptide-permeabilized synthetic vesicles to simulated gastric fluid and then to simulated intestinal fluid. The vesicles carry a reconstituted integral membrane protein and an encapsulated fluorescent tracer. Samples from each stage pass through a size-exclusion cartridge, and separate assays measure released tracer and antibody binding to the recovered vesicles.

Automated or data-driven variant

Automated measurement of vesicle leakage

A liquid handler dispenses synthetic vesicles with an integral membrane protein and an encapsulated dye into an assay plate. The handler adds lipopeptide surfactant to test wells and prepares untreated and fully disrupted vesicle controls. A plate reader records fluorescence over time, and software normalizes each time point to the controls and reports fractional dye release.

Specific version of a part

Single pass protein display

A membrane preparation from a nonpathogenic cell retains a reporter protein with one transmembrane helix. The helix anchors the protein in the lipid bilayer, and an exposed domain binds a detection antibody.

Multipass protein in membrane fragments

Plasma membrane fragments from a nonpathogenic cell retain a transporter with multiple transmembrane helices. The bilayer surrounds the hydrophobic helices, and an antibody binds an exposed loop of the transporter.

Permeability measured by dye entry

A fluorescence assay measures dye entry into permeabilized plasma membrane vesicles from nonpathogenic cells. An antibody signal measures the membrane protein in the same vesicle preparation.

Lipopeptide at a model interface

A synthetic lipopeptide with a fatty acyl tail and a charged peptide head acts as a surfactant in a cell free model. The tail associates with an oil droplet, and the peptide head contacts the surrounding water.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2018/0094320 A1
Published
Apr 5, 2018
Filed
Oct 3, 2017
Class
C12Q 1/6883
Document BUS 10,739,333 B2
Published
Aug 11, 2020
Filed
Sep 18, 2014
Class
G01N 33/5079
Claim 1
Document A
Document B
1.1a pathogen or a live vaccine thereof inactivated by permeabilization of the plasma membrane with a permeabilizer
The in vitro reagent is an admixture of metabolically competent cells and exogenous drug metabolizing enzyme co-factors follow by cryopreservation in the absence of cryopreservation agent so that the cells would be rendered permeable upon thawing due to plasma membrane disruption (while maintaining the integrity of organelles).
A · US 2018/0094320 A1 · abstract
To accomplish this, cells are immobilized on polyamine or poly-lysine coated surfaces and treated with low concentrations of digitonin in a mitochondrial buffer to permeabilize the plasma membrane and grant access to the mitochondria without cell disruption.
B · US 10,739,333 B2 · ¶ 71
1.2wherein the inactivated vaccine comprises a permeabilized plasma membrane and its integral membrane protein
To accomplish this, cells are immobilized on polyamine or poly-lysine coated surfaces and treated with low concentrations of digitonin in a mitochondrial buffer to permeabilize the plasma membrane and grant access to the mitochondria without cell disruption.
B · US 10,739,333 B2 · ¶ 71
1.3wherein the pathogen is a pathogen comprising a plasma membrane, and the permeabilizer comprises a lipopeptide as a surfactant.
To accomplish this, cells are immobilized on polyamine or poly-lysine coated surfaces and treated with low concentrations of digitonin in a mitochondrial buffer to permeabilize the plasma membrane and grant access to the mitochondria without cell disruption.
B · US 10,739,333 B2 · ¶ 71

An empty cell means only that no passage was reproduced there.

Statements in these documents
The invention relates to in vitro reagents for evaluating xenobiotic metabolism, methods of manufacturing the reagent and their methods of use for evaluating xenobiotic metabolism and as an exogenous metabolic system for cell culture assays with metabolic incompetent cells (cells that are not capable of xenobiotic metabolism).
A · US 2018/0094320 A1 · ¶ 3
To overcome this major defect of in vitro experimental systems, an exogenous metabolic system is needed to provide xenobiotic metabolism to these cell culture assays.
A · US 2018/0094320 A1 · ¶ 5
An increase in mitochondrial membrane permeabilization in the test cell population compared to the control cell population indicates the cell is sensitive to the therapeutic agent.
B · US 10,739,333 B2 · ¶ 7
Optionally, the cell is permeabilized prior to contacting with said BH3 domain peptide.
B · US 10,739,333 B2 · ¶ 7
Cite aspatent.fyi, US 2026/0355307 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355307/, SHA-256 ebeee39d78af76ba7e2e922e4f5c84c203e8ae133d80059695c0c80f47ff7781
First published
Permanent addresshttps://patent.fyi/US20260355307/
Content fingerprint (SHA-256)ebeee39d78af76ba7e2e922e4f5c84c203e8ae133d80059695c0c80f47ff7781
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi